| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Andrea Hermann, Christoph Benke, Carlo R Blecker, Benjamin de Haas, Yifei He, Stefan G Hofmann, Jona R Iffland, Johanna Jengert-Stahl, Tilo Kircher, Katrin Leinweber, Marcel Linka, Christoph Mulert, Marie K Neudert, Ann-Kathrin Noll, Christiane A Melzig, Winfried Rief, Constantin Rothkopf, Axel Schäfer, Christina V Schmitter, Verena Schuster, Rudolf Stark, Benjamin Straube, Raphaela I Zimmer, Lukas Kirchne. Study protocol TransTAM: Transdiagnostic research into emotional disorders and cognitive-behavioral therapy of the adaptive mind. BMC psychiatry. vol 24. issue 1. 2024-10-05. PMID:39369190. |
emotional disorders such as depression and anxiety disorders share substantial similarities in their etiology and treatment. |
2024-10-05 |
2024-10-08 |
Not clear |
| Mohamed Salih, Reem Mohamed Osman, Wala Alim, Leena Khalid, Wafa Sosal, Danya Ibrahim, Yassir Mahgou. Agitated Depression Associated With Flurazepam Discontinuation. Case reports in psychiatry. vol 2024. 2024-09-30. PMID:39345783. |
we describe a case of a 73-year-old female with a prior history of depression and generalized anxiety disorder who was maintained on flurazepam for 44 years and was admitted for severe depression with psychomotor agitation, prominent vegetative symptoms, thought perseveration, indecisiveness, and psychotic features that emerged following the discontinuation of flurazepam. |
2024-09-30 |
2024-10-02 |
Not clear |
| Almudena Cano-Crespo, Inmaculada Moreno-García, Mateu Servera, Manuel Morales-Orti. Emotional Regulation Problems in Cognitive Disengagement Syndrome (formerly Sluggish Cognitive Tempo), Attention Deficit and Hyperactivity Disorder, Anxiety and Depression. The Spanish journal of psychology. vol 27. 2024-09-25. PMID:39320849. |
emotional regulation problems in cognitive disengagement syndrome (formerly sluggish cognitive tempo), attention deficit and hyperactivity disorder, anxiety and depression. |
2024-09-25 |
2024-09-27 |
human |
| Kayla McElhany, Seema Aggarwal, Geri Wood, Jennifer Beaucham. Protective and harmful social and psychological factors associated with mood and anxiety disorders in perimenopausal women: A narrative review. Maturitas. vol 190. 2024-09-24. PMID:39317031. |
therefore, the purpose of this narrative review was to synthesize the findings of studies examining associations between social and psychological factors and the development of mood and anxiety disorders and the symptoms of depression and anxiety during perimenopause. |
2024-09-24 |
2024-09-27 |
Not clear |
| Mahsa Sadat Hayati, Jamal Shams, Sara Sadeghipour Meibodi, Amir Hossein Shafighi, Mona Shattell, Fataneh Ghadiria. The effects of a telenursing scheduled intervention of brief behavioral activation therapy on depression and anxiety symptoms of patients with mixed depression and anxiety disorder: A randomized controlled trial. Archives of psychiatric nursing. vol 52. 2024-09-11. PMID:39260982. |
the effects of a telenursing scheduled intervention of brief behavioral activation therapy on depression and anxiety symptoms of patients with mixed depression and anxiety disorder: a randomized controlled trial. |
2024-09-11 |
2024-09-14 |
Not clear |
| Tianyue Fan, Lingxiao Li, Yi Che. Causal relationships between gut microbiota and depression/anxiety disorders: A 2-sample Mendelian randomization study. Medicine. vol 103. issue 36. 2024-09-10. PMID:39252313. |
to investigate the potential causal relationship between the gm and depression/anxiety disorders and to identify specific bacterial taxa, we conducted a 2-sample mendelian randomization (mr) analysis on the gut microbiome implicated in depression and anxiety disorders. |
2024-09-10 |
2024-09-13 |
Not clear |
| Zifan Zhen, Xueqiang Sun, Shiying Yuan, Jiancheng Zhan. Psychoactive substances for the treatment of neuropsychiatric disorders. Asian journal of psychiatry. vol 101. 2024-09-07. PMID:39243659. |
hallucinogens like lysergic acid diethylamide and psilocybin primarily target the 5-ht2a receptor agonist-2 (5-ht2ar), inducing substantial perceptual and cognitive shifts that facilitate deep psychological introspection and significant therapeutic advances, particularly in patients suffering from depression and anxiety disorders. |
2024-09-07 |
2024-09-10 |
Not clear |
| Sasha Bailey, Ashleigh Lin, Angus Cook, Sam Winter, Vanessa Watson, Dani Wright Toussaint, Emma L Barrett, Nicola C Newton, Yael Perry, Lucinda Grummitt, Penelope Straus. Contextualising Experiences of Co-Occurring Mental Ill-Health and Substance Use Among Trans, Non-Binary, and Gender Diverse Young People: Implications for Tailored Harm Reduction Approaches. Community mental health journal. 2024-09-02. PMID:39222173. |
using data from the trans pathways study, we used prevalence ratios and age- and gender-adjusted logistic regression models to examine prevalence and differences of co-occurring substance use (past six-month cigarette use, alcohol use, and other drug use) and contextual characteristics of substance use (past six-month solitary alcohol and/or drug use, substance use for coping) by mental ill-health (depression disorder, anxiety disorder, past 12-month self-harm thoughts and behaviours, suicidal thoughts, planning, and attempt/s). |
2024-09-02 |
2024-09-04 |
Not clear |
| Marwa S Shafiek, Radwa Y Mekky, Noha N Nassar, Mohammed F El-Yamany, Mostafa A Rabi. Vortioxetine Ameliorates Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis in Mice via Activation of PI3K/Akt/CREB/BDNF cascade and Modulation of Serotonergic Pathway Signaling. European journal of pharmacology. 2024-08-24. PMID:39181226. |
vortioxetine (vtx), a multi-modal molecule prescribed to manage depression and anxiety disorder, additionally, it displays a promising neuroprotective properties against neurodegenerative diseases such as alzheimer's and parkinson's. |
2024-08-24 |
2024-08-28 |
mouse |
| Hubertus Himmerich, Jessica Bentley, Susan L McElro. Pharmacological Treatment of Binge Eating Disorder and Frequent Comorbid Diseases. CNS drugs. 2024-08-03. PMID:39096466. |
medications to treat diseases frequently comorbid with bed include atomoxetine and ldx for adhd; citalopram, fluoxetine, sertraline, duloxetine, and venlafaxine for anxiety disorders and depression; aripiprazole for manic episodes of bd; lamotrigine, lirasidone and lumateperone for depressive episodes of bd; naltrexone for alcohol use disorder; bupropion for nicotine use disorder; and liraglutide, semaglutide, and the combination of bupropion and naltrexone for obesity. |
2024-08-03 |
2024-08-06 |
Not clear |
| Jesse Markman, Heidi Comb. Newer Treatments for Mood and Anxiety Disorders. The Medical clinics of North America. vol 108. issue 5. 2024-07-31. PMID:39084841. |
for more than 20 years, the mainstay of pharmacologic treatment for depression and anxiety disorders has been serotonin reuptake inhibitors and selective serotonin and norepinephrine reuptake inhibitors. |
2024-07-31 |
2024-08-03 |
Not clear |
| Kurt A Jellinge. The Pathobiology of Behavioral Changes in Multiple System Atrophy: An Update. International journal of molecular sciences. vol 25. issue 13. 2024-07-13. PMID:39000570. |
while specific neuropathological data are unavailable, neuroimaging studies related anxiety disorders to changes in the cortico-limbic system, apathy (and depression) to dysfunction of prefrontal-subcortical circuits, and compulsive behaviors to impairment of basal ganglia networks and involvement of orbito-frontal circuits. |
2024-07-13 |
2024-07-15 |
Not clear |
| R Ruiz-Páez, J A López-Bueno, A Padrón-Monedero, M A Navas, P Salvador, C Linares, J Día. Short-term effects of fine particulate matter from biomass combustion and Saharan dust intrusions on emergency hospital admissions due to mental and behavioural disorders, anxiety and depression in Spain. The Science of the total environment. 2024-06-30. PMID:38945243. |
short-term effects of fine particulate matter from biomass combustion and saharan dust intrusions on emergency hospital admissions due to mental and behavioural disorders, anxiety and depression in spain. |
2024-06-30 |
2024-07-03 |
Not clear |
| Nathan T M Huneke, Jay Amin, David S Baldwin, Alessio Bellato, Valerie Brandt, Samuel R Chamberlain, Christoph U Correll, Luis Eudave, Matthew Garner, Corentin J Gosling, Catherine M Hill, Ruihua Hou, Oliver D Howes, Konstantinos Ioannidis, Ole Köhler-Forsberg, Lucia Marzulli, Claire Reed, Julia M A Sinclair, Satneet Singh, Marco Solmi, Samuele Cortes. Placebo effects in randomized trials of pharmacological and neurostimulation interventions for mental disorders: An umbrella review. Molecular psychiatry. 2024-06-24. PMID:38914807. |
placebo effect size varied, and was large in alcohol use disorder (g = 0.90, 95% ci [0.70, 1.09]), depression (g = 1.10, 95% ci [1.06, 1.15]), restless legs syndrome (g = 1.41, 95% ci [1.25, 1.56]), and generalized anxiety disorder (d = 1.85, 95% ci [1.61, 2.09]). |
2024-06-24 |
2024-06-27 |
Not clear |
| Joshin George Abraham, Nitha Thomas, Dr Sonia Shenoy, Dr Sebastian Padickaparambi. Feasibility and acceptability of an online group dialectical behavioural therapy skills training in a Transdiagnostic group with Anxiety and Depression. Psychiatry research. vol 339. 2024-06-22. PMID:38908264. |
this study assesses the feasibility and acceptability of online group dbt skills training for individuals with depression or anxiety disorders in india. |
2024-06-22 |
2024-06-25 |
human |
| Lori Calabrese, Rachel Frase, Mariam Ghalo. Complete remission of depression and anxiety using a ketogenic diet: case series. Frontiers in nutrition. vol 11. 2024-06-19. PMID:38887496. |
we present a retrospective case series of three adults with major depression and generalized anxiety disorder with complex comorbidity, treated with personalized ketogenic metabolic therapy, who achieved complete remission of major depression and generalized anxiety disorder and improvements in flourishing, self-compassion, and metabolic health. |
2024-06-19 |
2024-06-21 |
Not clear |
| Hanan S Althagafy, Emad H M Hassanei. Fluoxetine attenuates chlorpyrifos-induced neuronal injury through the PPARγ, SIRT1, NF-κB, and JAK1/STAT3 signals. International immunopharmacology. vol 136. 2024-06-15. PMID:38815349. |
fluoxetine (flx) is a selective serotonin reuptake inhibitor (ssri) that is widely prescribed for depression and anxiety disorders. |
2024-06-15 |
2024-06-18 |
rat |
| Indu Arora, Pankaj Mal, Poonam Arora, Anushka Paul, Manish Kuma. GABAergic implications in anxiety and related disorders. Biochemical and biophysical research communications. vol 724. 2024-06-12. PMID:38865810. |
a decrease in gabaergic activity is present in both anxiety disorders and severe depression. |
2024-06-12 |
2024-06-15 |
Not clear |
| William F Stubbeman, Jennifer Yang, Julianne Converse, Melodi Gencosmanoglu, Daisy Morales Ortega, Jordyn Morris, Andrew Sobocinski, Vicky Li, Gabriella Gunawardane, Yana Edelen, Raya Khairkhah, Jillian Pere. Neuronavigated Right Orbitofrontal 20 Hz Theta Burst Transcranial Magnetic Stimulation Augmentation for Obsessive-Compulsive Disorder with Comorbid Depression and Anxiety Disorders: An Open-Label Study. Brain sciences. vol 14. issue 5. 2024-05-25. PMID:38790461. |
neuronavigated 20 hz theta burst stimulation (tbs-20 hz), targeting the bilateral dorsolateral prefrontal cortex (dlpfc) augmented with the right orbitofrontal cortex (rofc), was tested for treating ocd comorbid with depression and anxiety disorders. |
2024-05-25 |
2024-05-27 |
Not clear |
| Marianne Côté-Olijnyk, J Christopher Perry, Marie-Ève Paré, Rachel Kronic. The mental health of migrants living in limbo: A mixed-methods systematic review with meta-analysis. Psychiatry research. vol 337. 2024-05-11. PMID:38733932. |
the meta-analysis yielded prevalence rates of 43.0 % for anxiety disorders (95 % ci 29.0-57.0), 49.5 % for depression (40.9-58.0) and 40.8 % for posttraumatic stress disorder (30.7-50.9). |
2024-05-11 |
2024-05-27 |
Not clear |